Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Toxicity profile of epcoritamab and glofitamab in aggressive B-cell lymphoma: A real-world analysis of CRS and icans in a single-center cohort

View Full Paper
Ask AI
Bookmark
Share

Authors

YZYumeng ZhangSGSameh GaballaHSHayder Saeed

Discussion

Loading...

Member takes

Overview

Real-world analysis reveals CRS and ICANS severity linked to baseline factors in B-cell lymphoma patients treated with bispecific antibodies.

Key Points

  • The study aims to assess the safety profiles of epcoritamab and glofitamab in patients with aggressive B-cell lymphoma, focusing on CRS and ICANS.
  • Analyzed data from 81 adults with B-cell non-Hodgkin lymphoma receiving either epcoritamab or glofitamab.
  • Measured CRS and ICANS severity using ASTCT criteria.
  • Examined baseline variables like inflammatory markers, ECOG status, and CNS involvement.
  • Utilized univariate ordinal logistic regression and Spearman correlation for analysis.
  • CRS occurred in 35.8% of patients, with 6.2% experiencing grades 3-4.
  • ICANS affected 16% of patients, with CNS involvement significantly increasing ICANS odds.
  • Higher baseline ferritin levels trended toward increased CRS severity, while lower hemoglobin predicted ICANS severity.
  • Notable rates of hypogammaglobulinemia and neutropenia observed, necessitating vigilant supportive care.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc3ahttps://doi.org/10.1182/blood-2025-8017
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Risk factors for cytokine release syndrome and neurotoxicity in patients receiving epcoritamab or glofitamab for large B cell lymphoma: A multi-center, retrospective, real world analysis.2025 · 1 citations
  2. 2Real-world experience with management of CRS and ICANS following CD3xCD20 bispecific antibody therapy.2026
  3. 3Risk factors for CRS and ICANS with Bispecific Antibodies for Aggressive Lymphomas2026
  4. 4Risk factors for CRS and NT with bispecific antibodies: Data from the American bispecifics and CART (ABC) consortium2025
  5. 5Clinical management of bispecific antibody therapy for lymphoma: A British Society for Haematology Good Practice Paper2025 · 3 citations